2020
Characterization of Wnt signaling pathway (WSP) aberrations in advanced prostate cancer.
Ghali F, Patel D, Jamieson C, Parsons J, McKay R. Characterization of Wnt signaling pathway (WSP) aberrations in advanced prostate cancer. Journal Of Clinical Oncology 2020, 38: 203-203. DOI: 10.1200/jco.2020.38.6_suppl.203.Peer-Reviewed Original ResearchProstate cancerOverall survivalActivating mutationsDe novo metastatic diseaseAdvanced prostate cancerSomatic activating mutationsEligible patientsAdvanced diseaseGleason 8Visceral metastasesClinical characteristicsMetastatic diseaseOverall cohortMedian ageMedian timePCa patientsDisease characteristicsOutcome parametersCRPC developmentBiomarker statusDisease progressionMultiple malignanciesTreatment strategiesClinical significanceBRCA1/2 alterations
2015
Patients with Biopsy Gleason 9 and 10 Prostate Cancer Have Significantly Worse Outcomes Compared to Patients with Gleason 8 Disease
Tsao C, Gray K, Nakabayashi M, Evan C, Kantoff P, Huang J, Galsky M, Pomerantz M, Oh W. Patients with Biopsy Gleason 9 and 10 Prostate Cancer Have Significantly Worse Outcomes Compared to Patients with Gleason 8 Disease. Journal Of Urology 2015, 194: 91-97. PMID: 25623747, DOI: 10.1016/j.juro.2015.01.078.Peer-Reviewed Original ResearchConceptsDefinitive local therapyGleason 8 diseaseGleason score 8Gleason 9Increased risk of deathRadiation therapyLocal therapyRisk of deathIncreased riskGleason 8Radical prostatectomyScore 8Associated with higher prostate specific antigenPatients treated with radical prostatectomyBiopsy Gleason score 8Gleason 9-10 diseaseHigher prostate specific antigenNeoadjuvant/adjuvant androgen deprivation therapyAndrogen deprivation therapyHigh grade diseaseBaseline patient characteristicsProstate specific antigenMultivariate Cox modelMedian followupBiochemical recurrence
2012
The impact of neoadjuvant weekly ixabepilone for high-risk prostate cancer: A phase I/II clinical trial.
Layton J, Plette A, Renzulli J, Miller E, Safran H, Mega A. The impact of neoadjuvant weekly ixabepilone for high-risk prostate cancer: A phase I/II clinical trial. Journal Of Clinical Oncology 2012, 30: 158-158. DOI: 10.1200/jco.2012.30.5_suppl.158.Peer-Reviewed Original ResearchHigh-risk prostate cancerPhase I/II clinical trialsPathologic complete responsePositive surgical marginsWeekly ixabepiloneProstate cancerAdverse eventsPSA responseComplete responseSurgical marginsPSA valuesClinical trialsPositive regional lymph nodesCessation of chemotherapyPre-operative PSAPretreatment Gleason scorePhase II studyRisk prostate cancerHigh-risk diseaseRegional lymph nodesBiochemical recurrence rateMetastatic prostate cancerTime of reviewCT3 diseaseGleason 8
2010
Analysis of pathologic extent of disease for clinically localized prostate cancer after radical prostatectomy and subsequent use of adjuvant radiation in a national cohort
Schreiber D, Rineer J, Yu J, Olsheski M, Nwokedi E, Schwartz D, Choi K, Rotman M. Analysis of pathologic extent of disease for clinically localized prostate cancer after radical prostatectomy and subsequent use of adjuvant radiation in a national cohort. Cancer 2010, 116: 5757-5766. PMID: 20737571, DOI: 10.1002/cncr.25561.Peer-Reviewed Original ResearchConceptsProstate-specific antigenClinically localized prostate cancerPositive surgical marginsLocalized prostate cancerAdjuvant radiationRadical prostatectomySurgical marginsProstate cancerPathologic extentRate of organ-confined diseaseProstate-specific antigen levelRisk of extraprostatic extensionPatterns of care studyOrgan-confined diseaseNegative surgical marginsEnd Results databaseLogistic regression analysisPopulation-based studyExtraprostatic diseaseExtraprostatic extensionGleason 7Gleason 8Postoperative radiationProstatic adenocarcinomaResults database
2009
A phase II study of neoadjuvant chemotherapy with docetaxel and bevacizumab in patients (pts) with high-risk localized prostate cancer: A Prostate Cancer Clinical Trials Consortium trial
Oh W, Febbo P, Richie J, Fennessy F, Scibelli G, Hayes J, Choueiri T, Tempany C, Taplin M, Ross R. A phase II study of neoadjuvant chemotherapy with docetaxel and bevacizumab in patients (pts) with high-risk localized prostate cancer: A Prostate Cancer Clinical Trials Consortium trial. Journal Of Clinical Oncology 2009, 27: 5060-5060. DOI: 10.1200/jco.2009.27.15_suppl.5060.Peer-Reviewed Original ResearchHigh-risk localized prostate cancerLocalized prostate cancerProstate cancerPSA declineGleason 7Neoadjuvant docetaxelRadical prostatectomyPhase II study of neoadjuvant chemotherapyClinical evidence of activityGrade 3 allergic reactionStudy of neoadjuvant chemotherapyPhase II multicenter trialBladder neck injuryMaximal tumor volumeMedian Gleason scoreTreated with docetaxelPhase II studyIntraoperative rectal injuryCT2 diseaseCT3 diseaseMedian PSARising PSAFebrile neutropeniaGleason 8Gleason score
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply